Please assess the completion status of the following clinical trial:

Trial Title: Safety of and Immune Response to an Adenoviral HIV-1 Vaccine in Healthy Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Good general health with normal hematological, hepatic and renal functions~* Demonstrated understanding of study~* Willing to receive HIV test results~* HIV-1 and -2 uninfected~* Hepatitis B surface antigen negative~* Anti-hepatitis C virus (anti-HCV) negative antibody or negative HCV PCR if anti-HCV is positive~* Appropriate hemoglobin, white blood cell, lymphocyte, and platelet count values as defined in the study protocol~* Certain laboratory values as defined in the study protocol~* Adequate contraception from at least 21 days prior to study entry through visit 10~Exclusion Criteria:~* HIV vaccines or placebos in prior HIV vaccine trial~* Immunosuppressive medications within 168 days prior to first injection. Participants taking corticosteroid nasal spray or topical corticosteroids are not excluded.~* Blood products within 120 days prior to first injection~* Immunoglobulin within 60 days prior to first injection~* Investigational agents within 30 days prior to first injections~* Live attenuated vaccine within 30 days prior to first injection~* Any vaccine not a live attenuated vaccine within 14 days prior to first injection~* Any clinically significant medical condition that, in the opinion of the investigator, may interfere with the study~* Any medical, psychiatric, occupational, or social condition or responsibility that, in the opinion of the investigator, would interfere with the study~* Serious adverse reaction to vaccines. Participants who had a nonanaphylactic adverse reaction to pertussis vaccine as a child are not excluded.~* Known autoimmune disease~* Known immunodeficiency~* Asthma other than mild and/or well-controlled asthma~* Active syphilis infection. Those fully treated for syphilis over 6 months prior to study entry are not excluded.~* Diabetes mellitus type 1 or 2~* Thyroidectomy or thyroid disease requiring medication within 12 months prior to study entry~* Angioedema in the 3 years prior to study entry if the episodes are considered serious or have required medication within the last 2 years~* Hypertension. More information on this criterion can be found in the protocol.~* Body mass index (BMI) of 40 or higher OR BMI of 35 or greater, if other cardiovascular risk factors. More information on this criterion can be found in the protocol.~* Bleeding disorder~* Malignancy, unless it has been surgically removed and, in the opinion of the investigator, is not likely to recur during the study period~* Seizure disorder or occurrence of seizure in the 3 years prior to study entry. Participants who have not required medications or had a seizure for prior 3 years are not excluded.~* Absence of a functional spleen~* Psychiatric condition within the last 3 years. More information on this criterion can be found in the study protocol.~* Individuals at high-risk of acquiring HIV infection~* Presence of pre-existing neutralizing antibodies for Adenovirus 26~* Pregnancy or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): 3 injections of Ad26.ENVA.01 HIV-1 vaccine or placebo at 1 x 10\^9 virus particles (VP) given at Days 0, 28, and 168
- 2 (Type: EXPERIMENTAL): 3 injections of Ad26.ENVA.01 HIV-1 vaccine or placebo at 1 x 10\^10 VP given at Days 0, 28, and 168
- 3 (Type: EXPERIMENTAL): 3 injections of Ad26.ENVA.01 HIV-1 vaccine or placebo at 1 x 10\^11 VP given at Days 0, 28, and 168
- 4 (Type: EXPERIMENTAL): 2 injections of Ad26.ENVA.01 HIV-1 vaccine or placebo at a dose to be determined by the safety data from Arms 1, 2 and 3 given at Days 0 and 168

Based on this trial design, predict the completion outcome and termination type (if applicable).